In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Rocket Pharmaceuticals Inc (NASDAQ: RCKT) closed at $6.33 in the last session, up 2.93% from day before closing price of $6.15. In other words, the price has increased by $2.93 from its previous closing price. On the day, 2.2 million shares were traded. RCKT stock price reached its highest trading level at $6.39 during the session, while it also had its lowest trading level at $6.09.
Ratios:
We take a closer look at RCKT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.30 and its Current Ratio is at 9.30. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BMO Capital Markets on March 12, 2025, initiated with a Outperform rating and assigned the stock a target price of $50.
On December 30, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $32.
On December 18, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $29.Jefferies initiated its Buy rating on December 18, 2024, with a $29 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 10 ’25 when Shah Gaurav bought 20,000 shares for $5.08 per share. The transaction valued at 101,600 led to the insider holds 792,680 shares of the business.
Patel Kinnari bought 21,099 shares of RCKT for $99,165 on Apr 09 ’25. The insider now owns 26,774 shares after completing the transaction at $4.70 per share. On Apr 09 ’25, another insider, White Mark Andrew, who serves as the Former Officer of the company, bought 3,382 shares for $4.67 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCKT now has a Market Capitalization of 674967872 and an Enterprise Value of 328128000.
Stock Price History:
The Beta on a monthly basis for RCKT is 1.05, which has changed by -0.7223684 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, RCKT has reached a high of $26.98, while it has fallen to a 52-week low of $4.55. The 50-Day Moving Average of the stock is -23.17%, while the 200-Day Moving Average is calculated to be -56.64%.
Shares Statistics:
According to the various share statistics, RCKT traded on average about 2.19M shares per day over the past 3-months and 4426600 shares per day over the past 10 days. A total of 106.45M shares are outstanding, with a floating share count of 98.96M. Insiders hold about 7.20% of the company’s shares, while institutions hold 101.67% stake in the company. Shares short for RCKT as of 1743379200 were 12437730 with a Short Ratio of 5.68, compared to 1740700800 on 11035189. Therefore, it implies a Short% of Shares Outstanding of 12437730 and a Short% of Float of 21.260001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Rocket Pharmaceuticals Inc (RCKT) is currently drawing attention from 13.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.23 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$0.3 and -$3.37 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$1.63, with 17.0 analysts recommending between -$0.04 and -$2.51.
Revenue Estimates
Based on 13 analysts’ estimates, the company’s revenue will be $99.91M in the next fiscal year. The high estimate is $235.6M and the low estimate is $7.43M.
